Spero Therapeutics, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, has announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The company is dedicated to identifying and developing treatments for rare diseases as well as multi-drug resistant (MDR) bacterial infections.
One of their lead product candidates, SPR720, is being developed as an oral, first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), with a Phase 2A proof of concept study underway. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections. Another investigational oral drug being tested in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, is Tebipenem HBr. Spero Therapeutics has granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except for certain Asian territories.
SPR206 is an innovative, investigational IV-administered direct-acting next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens in preclinical studies. An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information about Spero Therapeutics and their pipeline, interested parties can visit their website at https://sperotherapeutics.com. For investor relations, contact Ashley R. Robinson at LifeSci Advisors, LLC at arr@lifesciadvisors.com or (617) 775-5956. For media inquiries